Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)

Published:2014-01 Issue:6 Volume:100 Page:612-619
ISSN:0300-8916
Container-title:Tumori Journal
language:en
Short-container-title:Tumori Journal

Author:

Ferrari Stefano¹,Meazza Cristina²,Palmerini Emanuela¹,Tamburini Angela³,Fagioli Franca⁴,Cozza Raffaele⁵,Ferraresi Virginia⁶,Bisogno Gianni⁷,Mascarin Maurizio⁸,Cefalo Graziella²,Manfrini Marco¹,Capanna Rodolfo³,Biagini Roberto⁶,Donati Davide¹,Picci Piero¹

Affiliation:

1. Istituto Ortopedico Rizzoli, Bologna

2. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

3. Ospedale Meyer/Azienda Ospedaliera Universitaria Careggi, Florence

4. Ospedale Infantile Regina Margherita, Turin

5. Ospedale Pediatrico Bambin Gesù, Rome

6. Istituto Regina Elena, Rome

7. Pediatric Oncology, University of Padua, Padua

8. Centro di Riferimento Oncologico, Aviano (PN), Italy

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1778.19262

Reference17 articles.

1. Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009

2. Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

3. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1

4. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute

5. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance;European Journal of Medical Research;2023-09-16

2. Polymer-based nanosystems and their applications in bone anticancer therapy;Frontiers in Chemistry;2023-07-06

3. Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes;Current Oncology;2023-06-27

4. Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS‐2);Cancer;2022-02-24

5. Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study;Pediatric Blood & Cancer;2022-01-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3